
    
      A randomized, double blind, placebo-controlled, pilot clinical trial will carried out in 42
      patients with a diagnosis of prediabetes, according to the American Diabetes Association
      criteria. The patients will be divide in three groups administrating metformin plus placebo,
      melatonin plus placebo or melatonin plus metformin. The intervention will be with 500 mg
      lengthed release tablets of metformin once a day in the morning, per 90 days, 5 mg lengthed
      release capsules of melatonin one a day in the night per 90 days and calcined magnesia as a
      placebo. Before and after the intervention, will be evaluate: fasting plasma glucose, blood
      glucose after an oral glucose tolerance test, A1c hemoglobin fraction, micronuclei frequency,
      nuclear anomalies frequency, insulin secretion and insulin sensitivity, weight, height, body
      mass index, triglycerides, total cholesterol, high-density lipoprotein, low-density
      lipoprotein, creatinine, uric acid, and sleep quality.
    
  